![rapt therapeutics stock forecast rapt therapeutics stock forecast](https://s3.tradingview.com/p/p1zKn6HP_mid.png)
As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter.
![rapt therapeutics stock forecast rapt therapeutics stock forecast](https://media.marketrealist.com/brand-img/SIj7DFwwB/0x0/is-nuvve-nvve-stock-a-good-buy-1621339521095.png)
Use the PitchBook Platform to explore the full. What’s the forecast for the stock in 2021 and is it a good stock to buy in June 2021 Rapt Therapeutics is a clinical-stage biopharmaceutical company working on advancing the treatment for cancer and inflammation. Fundamental company data provided by Zacks Investment Research. Information on stock, financials, earnings, subsidiaries, investors, and executives for RAPT Therapeutics. Rapt Therapeutics (RAPT) stock rose over 115 yesterday and is trading higher in US premarket price action today also. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US0.56. To see all exchange delays and terms of use please see disclaimer. (NASDAQ:RAPT) missed earnings with its latest first-quarter results, disappointing overly-optimistic forecasters.It was not a great statutory result, with revenues coming in 85 lower than the analysts predicted. Create real-time notifications to follow any changes in the live stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View todays RAPT Therapeutics Inc stock price and latest RAPT news and analysis. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. RAPT stock price today + long-term Rapt Therapeutics - RAPT stock price, relative strength, and seasonality charts to give you perspective on todays RAPT. Our Accessibility Statement | Do Not Sell My Information does not provide financial advice and does not issue recommendations or offers to buy stock or Apple Inc stock Price is close to 10-year high. The consensus view seems to have become more. RAPT Stock warning signs - RAPT Therapeutics Inc : GuruFocus did a checkup and found warning signs for. Prior to the latest estimates, the analysts were forecasting revenues of US3.3m in 2020. keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. Following the downgrade, the current consensus from RAPT Therapeutics five analysts is for revenues of US2.9m in 2020 which - if met - would reflect a major 213 increase on its sales over the past 12 months.
![rapt therapeutics stock forecast rapt therapeutics stock forecast](https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2012/price_targets_218.png)
provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price targetĬhanges. was incorporated in 2015 and is headquartered in South San Francisco, California.© American Consumer News, LLC dba ® 2010-2021. and changed its name to RAPT Therapeutics, Inc. The company was formerly known as FLX Bio, Inc. RAPT Therapeutics NASDAQ Updated 10:12 PM. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. RAPT RAPT Therapeutics Stock Price and Discussion Stocktwits. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
RAPT THERAPEUTICS STOCK FORECAST TRIAL
Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. For the RAPT Therapeutics Inc forecast (traded under symbol RAPT) for one year forward price target at the top of this page, we have presented the average RAPT forecast for forward target price across the 5 analysts covering RAPT, as reported in data provided by Zacks Investment Research via.